Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 103848502 | 10384850 | 2 | F | 20160829 | 20140814 | 20160906 | EXP | US-PFIZER INC-2014225658 | PFIZER | AGGARWAL, R.. A PATIENT WITH MULTIPLE EPISODES OF RHABDOMYOLYSIS INDUCED BY DIFFERENT NEUROLEPTICS. REACTIONS 1512. 2014;9-10 | 23.00 | YR | M | Y | 0.00000 | 20160906 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 103848502 | 10384850 | 1 | SS | QUETIAPINE FUMARATE. | QUETIAPINE FUMARATE | 1 | Oral | 75 MG DAILY (25 MG IN THE MORNING AND 50 MG AT BEDTIME) | Y | 0 | 75 | MG | FILM-COATED TABLET | ||||||
| 103848502 | 10384850 | 2 | SS | QUETIAPINE FUMARATE. | QUETIAPINE FUMARATE | 1 | Oral | 100 MG, 2X/DAY | Y | 0 | 100 | MG | FILM-COATED TABLET | BID | |||||
| 103848502 | 10384850 | 3 | PS | ZIPRASIDONE HCL | ZIPRASIDONE HYDROCHLORIDE | 1 | Oral | 60 MG, 2X/DAY | Y | 20825 | 60 | MG | BID | ||||||
| 103848502 | 10384850 | 4 | SS | PALIPERIDONE. | PALIPERIDONE | 1 | Oral | 3 MG, DAILY AT THIS TIME | Y | 0 | 3 | MG | |||||||
| 103848502 | 10384850 | 5 | SS | PALIPERIDONE. | PALIPERIDONE | 1 | Oral | 9 MG, DAILY BY DISCHARGE | Y | 0 | 9 | MG | |||||||
| 103848502 | 10384850 | 6 | SS | HALOPERIDOL. | HALOPERIDOL | 1 | Oral | 5 MG, DAILY | Y | 0 | 5 | MG | |||||||
| 103848502 | 10384850 | 7 | SS | LITHIUM. | LITHIUM | 1 | Oral | 900 MG, DAILY ON OUTPATIENT FOLLOW UP | Y | 0 | 900 | MG | |||||||
| 103848502 | 10384850 | 8 | C | BENZATROPINE | BENZTROPINE | 1 | Oral | 1 MG, 2X/DAY | 0 | 1 | MG | BID | |||||||
| 103848502 | 10384850 | 9 | C | CLONAZEPAM. | CLONAZEPAM | 1 | Oral | 1 MG, 2X/DAY | 0 | 1 | MG | BID | |||||||
| 103848502 | 10384850 | 10 | C | OLANZAPINE. | OLANZAPINE | 1 | Oral | 10 MG, 2X/DAY | 0 | 10 | MG | BID | |||||||
| 103848502 | 10384850 | 11 | C | OLANZAPINE. | OLANZAPINE | 1 | Oral | 20 MG, 1X/DAY (AT BED TIME) | 0 | 20 | MG | QD | |||||||
| 103848502 | 10384850 | 12 | C | VALPROIC ACID. | VALPROIC ACID | 1 | Oral | 500 MG, 2X/DAY | 0 | 500 | MG | BID |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 103848502 | 10384850 | 1 | Schizoaffective disorder |
| 103848502 | 10384850 | 3 | Schizoaffective disorder |
| 103848502 | 10384850 | 4 | Schizoaffective disorder |
| 103848502 | 10384850 | 6 | Schizoaffective disorder |
| 103848502 | 10384850 | 7 | Schizoaffective disorder |
| 103848502 | 10384850 | 12 | Schizoaffective disorder |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 103848502 | 10384850 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 103848502 | 10384850 | Abdominal pain | |
| 103848502 | 10384850 | Alanine aminotransferase increased | |
| 103848502 | 10384850 | Aspartate aminotransferase increased | |
| 103848502 | 10384850 | Back pain | |
| 103848502 | 10384850 | Blood creatine phosphokinase increased | |
| 103848502 | 10384850 | Dyspnoea | |
| 103848502 | 10384850 | Muscle rigidity | |
| 103848502 | 10384850 | Pain | |
| 103848502 | 10384850 | Rhabdomyolysis | |
| 103848502 | 10384850 | Tachypnoea |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |